drugset / Trial / NCT01302899

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

NCT01302899

Phase 2 Terminated 8 enrolled Novartis Pharmaceuticals
RandomizedCrossoverSingle-blindTreatment

Summary

The study is designed to primarily assess the effect of aliskiren on albuminuria in patients with non-diabetic nephropathy when treated with ramipril and volume intervention.

Timeline

Start
2011-01
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Hydrochlorothiazide Unknown 25 mg
Background Ramipril Small molecule 10 mg

Indications

No indication recorded.